Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

View Full Paper
Ask AI
Bookmark
Share

Authors

BABertrand AnzUniversity of Tennessee at ChattanoogaDWDavid WrightAstraZeneca (United Kingdom)VCVivek S. ChopraAmgen (United States)

Discussion

Loading...

Member takes

Implication

Phase II trial reveals improved progression-free survival with maintenance treatment in high-tumor burden follicular lymphoma.

Key Points

  • To evaluate the efficacy and safety of subcutaneous mosunetuzumab in untreated high-tumor burden follicular lymphoma.
  • Phase II trial with a fixed-duration treatment schedule.
  • Patients received mosunetuzumab subcutaneously with optional maintenance therapy.
  • Follow-up assessed progression-free survival and adverse events.
  • 12-month progression-free survival rate was 85.5%.
  • 87.4% objective response rate and 64.1% complete metabolic response observed.
  • Adverse events were mostly grade 1/2, with COVID-19 pneumonia noted as a serious event.

Cite This Study

Anz et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc5bhttps://doi.org/10.1182/blood-2025-228
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma2025 · 1 citations
  2. 2Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations
  3. 3Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study2025 · 6 citations
  4. 4Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study2025 · 3 citations
  5. 5Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.2026